EMA Authorised: Cyramza (ramucirumab) — Eli Lilly Nederland B.V.

View source ↗

Summary

The EMA has authorised Cyramza (ramucirumab) for gastric cancer (stomach neoplasms) in the European Union, with Eli Lilly Nederland B.V. as the marketing author…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Cyramza (ramucirumab)

Snippet

Status: Authorised. Therapeutic area: Stomach Neoplasms. MAH: Eli Lilly Nederland B.V.. Decision date: 16/01/2026